AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 11978287 — intervention group
Group type: COMPARATOR
Intervention: Observation
Number of subjects: 117
Study 10760294 — intervention group
Group type: EXPERIMENTAL
Intervention: DHEA, 50 mg, orally, daily for a year
Number of subjects: 280
Study 10760294 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 280
Study 8933125 — intervention group
Group type: EXPERIMENTAL
Intervention: Fish diet (4.3 meals per week for 15 weeks)
Number of subjects: 55
Study 8933125 — intervention group
Group type: EXPERIMENTAL
Intervention: Fish oil (4 g oil per day for 15 weeks)
Number of subjects: 55
Study 8933125 — intervention group
Group type: EXPERIMENTAL
Intervention: DHA-rich oil (4 g oil per day for 15 weeks)
Number of subjects: 55
Study 8933125 — intervention group
Group type: COMPARATOR
Intervention: Control group (not specified)
Number of subjects: 55
Study 8933125 — intervention group
Group type: EXPERIMENTAL
Intervention: All test groups (Fish diet, Fish oil, DHA-rich oil)
Number of subjects: 55
Study 8933125 — intervention group
Group type: EXPERIMENTAL
Intervention: Fish diet and Fish oil
Number of subjects: 55
Study 1434268 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral prostaglandin E1 (limaprost)
Number of subjects: 41
Study 1434268 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 41
Study 3902525 — intervention group
Group type: EXPERIMENTAL
Intervention: Ambulation
Number of subjects: 57
Study 3902525 — intervention group
Group type: COMPARATOR
Intervention: Oxytocin
Number of subjects: 57
Study 30690085 — intervention group
Group type: EXPERIMENTAL
Intervention: Radiation therapy regimens (41 identified)
Number of subjects: 470
Study 30690085 — intervention group
Group type: EXPERIMENTAL
Intervention: Typical CT scan
Number of subjects: 470
Study 30690085 — intervention group
Group type: EXPERIMENTAL
Intervention: LADCA segments
Number of subjects: 470
Study 30690085 — intervention group
Group type: EXPERIMENTAL
Intervention: Individual regimens
Number of subjects: 470
Study 29357894 — intervention group
Group type: EXPERIMENTAL
Intervention: Standard Care + Enhanced Program
Number of subjects: 360
Study 29357894 — intervention group
Group type: COMPARATOR
Intervention: Standard Care Alone
Number of subjects: 360
Study 27328311 — intervention group
Group type: EXPERIMENTAL
Intervention: Nutritional intervention (dietary advice)
Number of subjects: 258
Study 27328311 — intervention group
Group type: EXPERIMENTAL
Intervention: Nutritional intervention (oral supplementation)
Number of subjects: 258
Study 27328311 — intervention group
Group type: EXPERIMENTAL
Intervention: Nutritional intervention (major intervention)
Number of subjects: 258
Study 27328311 — intervention group
Group type: COMPARATOR
Intervention: Cetuximab patients receiving major nutritional intervention
Number of subjects: 258
Study 24738467 — intervention group
Group type: COMPARATOR
Intervention: Shuganyiyang Capsules
Number of subjects: 90
Study 24738467 — intervention group
Group type: COMPARATOR
Intervention: Tadalafil
Number of subjects: 90
Study 24738467 — intervention group
Group type: COMPARATOR
Intervention: Tadalafil + Shuganyiyang Capsules
Number of subjects: 90
Study 23763511 — intervention group
Group type: EXPERIMENTAL
Intervention: Gemcitabine plus S-1 (GS)
Number of subjects: 101
Study 23763511 — intervention group
Group type: COMPARATOR
Intervention: S-1
Number of subjects: 101
Study 20804302 — intervention group
Group type: EXPERIMENTAL
Intervention: Directed forgetting (forget group)
Number of subjects: 0
Study 20804302 — intervention group
Group type: COMPARATOR
Intervention: Control remember group
Number of subjects: 0
Study 20804302 — intervention group
Group type: EXPERIMENTAL
Intervention: Directed forgetting with item-specific encoding
Number of subjects: 0
Study 19047702 — intervention group
Group type: EXPERIMENTAL
Intervention: Posterior cruciate ligament-substituting design
Number of subjects: 100
Study 19047702 — intervention group
Group type: COMPARATOR
Intervention: Posterior cruciate ligament-retaining design
Number of subjects: 100
Study 16005623 — intervention group
Group type: EXPERIMENTAL
Intervention: Budesonide/formoterol 160/4.5 microg (640/18 microg/day)
Number of subjects: 133
Study 16005623 — intervention group
Group type: COMPARATOR
Intervention: Budesonide 320 microg (1280 microg/day)
Number of subjects: 133
Study 16005623 — intervention group
Group type: EXPERIMENTAL
Intervention: Budesonide/formoterol
Number of subjects: 133
Study 12791820 — intervention group
Group type: EXPERIMENTAL
Intervention: 99mTc-ciprofloxacin scintigraphy
Number of subjects: 27
Study 10652395 — intervention group
Group type: EXPERIMENTAL
Intervention: Septoplasty surgery
Number of subjects: 161
Study 10652395 — intervention group
Group type: EXPERIMENTAL
Intervention: Nasal Health Survey
Number of subjects: 161
Study 10652395 — intervention group
Group type: EXPERIMENTAL
Intervention: General health measures (Short Form-12)
Number of subjects: 161
Study 8773887 — intervention group
Group type: EXPERIMENTAL
Intervention: Fibrin adhesive Tissucol
Number of subjects: 40
Study 8773887 — intervention group
Group type: COMPARATOR
Intervention: Conventional subciliary suturing (5-0 running suture)
Number of subjects: 40
Study 8773887 — intervention group
Group type: COMPARATOR
Intervention: Control group (no surgery)
Number of subjects: 40
Study 1361310 — intervention group
Group type: EXPERIMENTAL
Intervention: Dexmedetomidine 1.0 micrograms/kg
Number of subjects: 37
Study 1361310 — intervention group
Group type: EXPERIMENTAL
Intervention: Dexmedetomidine 2.0 micrograms/kg
Number of subjects: 37
Study 1361310 — intervention group
Group type: EXPERIMENTAL
Intervention: Dexmedetomidine (all doses)
Number of subjects: 37
Study 1361310 — intervention group
Group type: EXPERIMENTAL
Intervention: Dexmedetomidine 1.0 and 2.0 micrograms/kg
Number of subjects: 37
Study 1361310 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 37
Study 31671191 — intervention group
Group type: EXPERIMENTAL
Intervention: Olaparib and cediranib
Number of subjects: 68
Study 31671191 — intervention group
Group type: EXPERIMENTAL
Intervention: Olaparib and durvalumab
Number of subjects: 68
Study 31671191 — intervention group
Group type: EXPERIMENTAL
Intervention: Durvalumab and chemotherapy (high PD-L1 expression)
Number of subjects: 68
Study 31671191 — intervention group
Group type: EXPERIMENTAL
Intervention: Durvalumab, tremelimumab, and chemotherapy (low PD-L1 expression)
Number of subjects: 68
Study 28230798 — intervention group
Group type: EXPERIMENTAL
Intervention: Village-based nutrition intervention including nutritional education, written materials, and SMS
Number of subjects: 60
Study 28230798 — intervention group
Group type: EXPERIMENTAL
Intervention: Village-based nutrition intervention
Number of subjects: 60
Study 28230798 — intervention group
Group type: EXPERIMENTAL
Intervention: Folic acid education and SMS intervention
Number of subjects: 60
Study 26923574 — intervention group
Group type: EXPERIMENTAL
Intervention: Trans-Sylvian (TS) approach
Number of subjects: 18
Study 26923574 — intervention group
Group type: COMPARATOR
Intervention: Trans-Cortical (TC) approach
Number of subjects: 18
Study 23037612 — intervention group
Group type: EXPERIMENTAL
Intervention: Treadmill running (TR)
Number of subjects: 9
Study 23037612 — intervention group
Group type: EXPERIMENTAL
Intervention: Stationary running (SR)
Number of subjects: 9
Study 23037612 — intervention group
Group type: COMPARATOR
Intervention: Jumping jack (JJ)
Number of subjects: 9
Study 23037612 — intervention group
Group type: EXPERIMENTAL
Intervention: Forward kick (FK)
Number of subjects: 9
Study 23037612 — intervention group
Group type: COMPARATOR
Intervention: %V[Combining Dot Above]O2max
Number of subjects: 9
Study 23037612 — intervention group
Group type: COMPARATOR
Intervention: RPE
Number of subjects: 9
Study 21235330 — intervention group
Group type: EXPERIMENTAL
Intervention: Paper strips
Number of subjects: 36
Study 21235330 — intervention group
Group type: COMPARATOR
Intervention: Paper points
Number of subjects: 36
Study 21235330 — intervention group
Group type: EXPERIMENTAL
Intervention: Washing the periodontal pocket
Number of subjects: 36
Study 19207276 — intervention group
Group type: EXPERIMENTAL
Intervention: Testosterone and vardenafil
Number of subjects: 28
Study 17370714 — intervention group
Group type: EXPERIMENTAL
Intervention: Dietary restriction and physical activity with behaviour therapy
Number of subjects: 0
Study 17370714 — intervention group
Group type: EXPERIMENTAL
Intervention: Anti-obesity drugs
Number of subjects: 0
Study 17370714 — intervention group
Group type: EXPERIMENTAL
Intervention: Treatment programmes
Number of subjects: 0
Study 15366318 — intervention group
Group type: EXPERIMENTAL
Intervention: Bispectral index monitoring
Number of subjects: 0
Study 11120972 — intervention group
Group type: EXPERIMENTAL
Intervention: Concentration-controlled therapy (11 subjects)
Number of subjects: 24
Study 11120972 — intervention group
Group type: COMPARATOR
Intervention: Standard therapy (13 subjects)
Number of subjects: 24
Study 9711340 — intervention group
Group type: EXPERIMENTAL
Intervention: SPf66 vaccine
Number of subjects: 0
Study 9711340 — intervention group
Group type: COMPARATOR
Intervention: Placebo control
Number of subjects: 0
Study 7975357 — intervention group
Group type: EXPERIMENTAL
Intervention: Enalapril (ENAP KRKA)
Number of subjects: 20
Study 7975357 — intervention group
Group type: EXPERIMENTAL
Intervention: Metoprolol (Vasocardin Slovakofarma)
Number of subjects: 20
Study 2737801 — intervention group
Group type: EXPERIMENTAL
Intervention: Cimetidine
Number of subjects: 9
Study 2737801 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 9
Study 2737801 — intervention group
Group type: EXPERIMENTAL
Intervention: Roxatidine acetate hydrochloride
Number of subjects: 9
Study 31181144 — intervention group
Group type: EXPERIMENTAL
Intervention: EHR-based health information technology intervention
Number of subjects: 0
Study 28399980 — intervention group
Group type: EXPERIMENTAL
Intervention: Exercise
Number of subjects: 841
Study 28399980 — intervention group
Group type: COMPARATOR
Intervention: Control (no exercise)
Number of subjects: 841
Study 26493461 — intervention group
Group type: EXPERIMENTAL
Intervention: Home-based exercise programme delivered through a tablet computer, 2 hours of exercises per week for 2 years.
Number of subjects: 500
Study 26493461 — intervention group
Group type: COMPARATOR
Intervention: Education programme focused on health-related information relevant to older adults, delivered through the tablet computer via weekly fact sheets.
Number of subjects: 500
Study 24034466 — intervention group
Group type: EXPERIMENTAL
Intervention: E2 V/DNG
Number of subjects: 213
Study 24034466 — intervention group
Group type: COMPARATOR
Intervention: EE/LNG
Number of subjects: 213
Study 24034466 — intervention group
Group type: EXPERIMENTAL
Intervention: E2 V/DNG and EE/LNG
Number of subjects: 213
Study 19836218 — intervention group
Group type: EXPERIMENTAL
Intervention: Low GI and Low GL breakfast (LGI-LGL)
Number of subjects: 16
Study 19836218 — intervention group
Group type: EXPERIMENTAL
Intervention: High GI and High GL breakfast (HGI-HGL)
Number of subjects: 16
Study 19836218 — intervention group
Group type: EXPERIMENTAL
Intervention: High GI and Low GL breakfast (HGI-LGL)
Number of subjects: 16
Study 18643839 — intervention group
Group type: EXPERIMENTAL
Intervention: Basal-bolus therapy (insulin detemir once daily and insulin aspart mealtimes)
Number of subjects: 719
Study 18643839 — intervention group
Group type: COMPARATOR
Intervention: Biphasic insulin aspart 30 (30% rapid-acting insulin aspart), twice daily
Number of subjects: 719
Study 17848650 — intervention group
Group type: EXPERIMENTAL
Intervention: High doses of folic acid (40 mg), pyridoxine hydrochloride (100 mg), and cyanocobalamin (2 mg) daily
Number of subjects: 2056
Study 17848650 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 2056
Study 17848650 — intervention group
Group type: EXPERIMENTAL
Intervention: High doses of folic acid and B vitamins
Number of subjects: 2056
Study 15054373 — intervention group
Group type: EXPERIMENTAL
Intervention: Fluticasone propionate 400 microg/day after saline lavage
Number of subjects: 162
Study 15054373 — intervention group
Group type: EXPERIMENTAL
Intervention: Beclomethasone dipropionate 600 microg/day after saline lavage
Number of subjects: 162
Study 15054373 — intervention group
Group type: COMPARATOR
Intervention: Saline lavage only (Control group)
Number of subjects: 162
Study 11331147 — intervention group
Group type: EXPERIMENTAL
Intervention: Nicotine gum (6 mg)
Number of subjects: 11
Study 11331147 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 11
Study 9141924 — intervention group
Group type: EXPERIMENTAL
Intervention: Alfentanil (40 micrograms/kg IV bolus) followed by infusion (1 microgram.kg‐1.min‐1 during surgery and 0.5 microgram.kg‐1.min‐1 postoperatively)
Number of subjects: 14
Study 9141924 — intervention group
Group type: EXPERIMENTAL
Intervention: Sufentanil (5 micrograms/kg IV bolus) followed by infusion (0.01 microgram.kg‐1.min‐1 during surgery and 0.005 microgram.kg‐1.min‐1 postoperatively)
Number of subjects: 14
Study 9355669 — intervention group
Group type: EXPERIMENTAL
Intervention: Prednisone (more than 0.16 mg/kg/day for more than 6 months)
Number of subjects: 14
Study 9355669 — intervention group
Group type: COMPARATOR
Intervention: No corticosteroids
Number of subjects: 14
Study 2852609 — intervention group
Group type: EXPERIMENTAL
Intervention: Fluconazole, single oral 150 mg dose
Number of subjects: 183
Study 2852609 — intervention group
Group type: COMPARATOR
Intervention: Ketoconazole, 200 mg twice daily for 5 days
Number of subjects: 183
Study 30445389 — intervention group
Group type: EXPERIMENTAL
Intervention: Unified Protocol for the Transdiagnostic Treatment of Emotional Disorders (UP)
Number of subjects: 128
Study 30445389 — intervention group
Group type: COMPARATOR
Intervention: Waitlist/Treatment-as-Usual (WL/TAU)
Number of subjects: 128
Study 28785847 — intervention group
Group type: EXPERIMENTAL
Intervention: Diethylcarbamazine (DEC)
Number of subjects: 155
Study 28785847 — intervention group
Group type: EXPERIMENTAL
Intervention: Diethylcarbamazine (DEC) + Albendazole (ABZ)
Number of subjects: 155
Study 28785847 — intervention group
Group type: COMPARATOR
Intervention: Control (not specified)
Number of subjects: 155
Study 25761542 — intervention group
Group type: EXPERIMENTAL
Intervention: Serum methylglyoxal
Number of subjects: 882
Study 23963046 — intervention group
Group type: EXPERIMENTAL
Intervention: Sildenafil (doses: 37.5 mg, 50 mg, 100 mg)
Number of subjects: 26
Study 21873906 — intervention group
Group type: EXPERIMENTAL
Intervention: Assisted Sprint Training (AST)
Number of subjects: 27
Study 21873906 — intervention group
Group type: EXPERIMENTAL
Intervention: Resisted Sprint Training (RST)
Number of subjects: 27
Study 21873906 — intervention group
Group type: COMPARATOR
Intervention: Traditional Sprint Training (TST)
Number of subjects: 27
Study 19289615 — intervention group
Group type: EXPERIMENTAL
Intervention: p16(INK4A) positive tumors
Number of subjects: 156
Study 17210079 — intervention group
Group type: EXPERIMENTAL
Intervention: Buprenorphine
Number of subjects: 60
Study 17210079 — intervention group
Group type: COMPARATOR
Intervention: Dihydrocodeine
Number of subjects: 60
Study 15785088 — intervention group
Group type: EXPERIMENTAL
Intervention: Acyclic retinoid (oral administration for 12 months)
Number of subjects: 0
Study 12034658 — intervention group
Group type: EXPERIMENTAL
Intervention: Losartan treatment for 12 months in patients with severe fibrosis (n=7)
Number of subjects: 34
Study 12034658 — intervention group
Group type: COMPARATOR
Intervention: Control group (nonsevere fibrosis, n=12)
Number of subjects: 34
Study 12034658 — intervention group
Group type: EXPERIMENTAL
Intervention: All hypertensives
Number of subjects: 34
Study 10716202 — intervention group
Group type: EXPERIMENTAL
Intervention: Normal sleep
Number of subjects: 13
Study 10716202 — intervention group
Group type: COMPARATOR
Intervention: Sleep deprivation (SD)
Number of subjects: 13
Study 7790707 — intervention group
Group type: EXPERIMENTAL
Intervention: Propylthiouracil (300 mg)
Number of subjects: 8
Study 7790707 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 8
Study 2220013 — intervention group
Group type: EXPERIMENTAL
Intervention: 5 mg pimobendan
Number of subjects: 12
Study 2220013 — intervention group
Group type: EXPERIMENTAL
Intervention: 10 mg pimobendan
Number of subjects: 12
Study 87829 — intervention group
Group type: EXPERIMENTAL
Intervention: 2-month regimen of chemotherapy (daily streptomycin, isoniazid, rifampicin, and pyrazinamide)
Number of subjects: 1072
Study 87829 — intervention group
Group type: EXPERIMENTAL
Intervention: 3-month regimen of chemotherapy (daily streptomycin, isoniazid, rifampicin, and pyrazinamide)
Number of subjects: 1072
Study 87829 — intervention group
Group type: COMPARATOR
Intervention: Standard 12-month control regimen
Number of subjects: 1072
Study 31796570 — intervention group
Group type: EXPERIMENTAL
Intervention: Nonalbuminuric CKD
Number of subjects: 10185
Study 31796570 — intervention group
Group type: EXPERIMENTAL
Intervention: Albuminuric CKD
Number of subjects: 10185
Study 31796570 — intervention group
Group type: EXPERIMENTAL
Intervention: Albuminuric non-CKD
Number of subjects: 10185
Study 31796570 — intervention group
Group type: COMPARATOR
Intervention: No CKD
Number of subjects: 10185
Study 31124975 — intervention group
Group type: EXPERIMENTAL
Intervention: Pneumoperitoneum and steep Trendelenburg position
Number of subjects: 90
Study 28473058 — intervention group
Group type: EXPERIMENTAL
Intervention: Grape powder
Number of subjects: 0
Study 28473058 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study 25938681 — intervention group
Group type: EXPERIMENTAL
Intervention: Peer counselled promotion of exclusive breastfeeding (EBF) for 6 months
Number of subjects: 765
Study 25938681 — intervention group
Group type: COMPARATOR
Intervention: Standard of care (control)
Number of subjects: 765
Study 24284610 — intervention group
Group type: EXPERIMENTAL
Intervention: Chewable tablet (200 mg vitamin C)
Number of subjects: 9
Study 24284610 — intervention group
Group type: EXPERIMENTAL
Intervention: Kiwifruit-derived vitamin C (equivalent dose from gold kiwifruit)
Number of subjects: 9
Study 24284610 — intervention group
Group type: EXPERIMENTAL
Intervention: Kiwifruit-derived vitamin C
Number of subjects: 9
Study 24284610 — intervention group
Group type: COMPARATOR
Intervention: Vitamin C tablet
Number of subjects: 9
Study 24284610 — intervention group
Group type: EXPERIMENTAL
Intervention: Both interventions
Number of subjects: 9
Study 22152107 — intervention group
Group type: EXPERIMENTAL
Intervention: Group-based rehabilitation
Number of subjects: 143
Study 22152107 — intervention group
Group type: COMPARATOR
Intervention: Individual counselling
Number of subjects: 143
Study 19418107 — intervention group
Group type: COMPARATOR
Intervention: Generic print pamphlet
Number of subjects: 412
Study 19418107 — intervention group
Group type: EXPERIMENTAL
Intervention: Tailored print pamphlet
Number of subjects: 412
Study 19418107 — intervention group
Group type: EXPERIMENTAL
Intervention: Tailored print pamphlet and tailored counseling call
Number of subjects: 412
Study 16960663 — intervention group
Group type: EXPERIMENTAL
Intervention: Antireflux stent
Number of subjects: 41
Study 16960663 — intervention group
Group type: COMPARATOR
Intervention: Standard stent
Number of subjects: 41
Study 16960663 — intervention group
Group type: EXPERIMENTAL
Intervention: Both groups
Number of subjects: 41
Study 15496648 — intervention group
Group type: EXPERIMENTAL
Intervention: Amprenavir-containing combination therapy with nucleoside reverse transcriptase inhibitors
Number of subjects: 0
Study 15496648 — intervention group
Group type: EXPERIMENTAL
Intervention: C(min)/IC(50) ratio
Number of subjects: 0
Study 11783936 — intervention group
Group type: EXPERIMENTAL
Intervention: UVB irradiation
Number of subjects: 34
Study 11783936 — intervention group
Group type: COMPARATOR
Intervention: NFkappaB oligonucleotide decoy
Number of subjects: 34
Study 11783936 — intervention group
Group type: COMPARATOR
Intervention: Sodium salicylate
Number of subjects: 34
Study 9151545 — intervention group
Group type: COMPARATOR
Intervention: Not available
Number of subjects: 0
Study 8421205 — intervention group
Group type: EXPERIMENTAL
Intervention: Intrathecal baclofen (50, 75, or 100 micrograms)
Number of subjects: 93
Study 8421205 — intervention group
Group type: EXPERIMENTAL
Intervention: Intrathecal baclofen infusion
Number of subjects: 93
Study 3501546 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral leucovorin calcium (5-formyl-THF) at doses of 40 mg, 60 mg, 80 mg, and 100 mg
Number of subjects: 30
Study 3501546 — intervention group
Group type: EXPERIMENTAL
Intervention: 200 mg oral leucovorin calcium
Number of subjects: 30
Study 3501546 — intervention group
Group type: COMPARATOR
Intervention: 200 mg intravenous leucovorin calcium
Number of subjects: 30
Study 3501546 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral leucovorin calcium
Number of subjects: 30
Study 31537115 — intervention group
Group type: EXPERIMENTAL
Intervention: Mini-percutaneous nephrolithotomy (mPNL)
Number of subjects: 148
Study 31537115 — intervention group
Group type: COMPARATOR
Intervention: Standard percutaneous nephrolithotomy (sPNL)
Number of subjects: 148
Study 29215299 — intervention group
Group type: EXPERIMENTAL
Intervention: CSII therapy
Number of subjects: 23
Study 29215299 — intervention group
Group type: COMPARATOR
Intervention: MDI therapy
Number of subjects: 23
Study 29215299 — intervention group
Group type: EXPERIMENTAL
Intervention: CSII therapy at 12 months
Number of subjects: 23
Study 29215299 — intervention group
Group type: EXPERIMENTAL
Intervention: CSII therapy after crossover from MDI
Number of subjects: 23
Study 27780350 — intervention group
Group type: EXPERIMENTAL
Intervention: Text messaging
Number of subjects: 58
Study 27780350 — intervention group
Group type: COMPARATOR
Intervention: Email
Number of subjects: 58
Study 24766974 — intervention group
Group type: EXPERIMENTAL
Intervention: Amiodarone (up to 450 mg)
Number of subjects: 3000
Study 24766974 — intervention group
Group type: EXPERIMENTAL
Intervention: Lidocaine (up to 180 mg)
Number of subjects: 3000
Study 24766974 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 3000
Study 24766974 — intervention group
Group type: EXPERIMENTAL
Intervention: Amiodarone
Number of subjects: 3000
Study 24766974 — intervention group
Group type: EXPERIMENTAL
Intervention: Lidocaine
Number of subjects: 3000
Study 24135924 — intervention group
Group type: EXPERIMENTAL
Intervention: MLC601
Number of subjects: 1099
Study 24135924 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 1099
Study 21569282 — intervention group
Group type: EXPERIMENTAL
Intervention: WHS mental module with screening and feedback, plus consultation with an occupational physician for impairments in mental health or work functioning.
Number of subjects: 1731
Study 21569282 — intervention group
Group type: EXPERIMENTAL
Intervention: WHS mental module with tailored self-help e-mental health interventions based on individual mental health state and work functioning.
Number of subjects: 1731
Study 21569282 — intervention group
Group type: COMPARATOR
Intervention: Control group (no intervention).
Number of subjects: 1731